中性粒细胞缺乏合并脓毒症时前B细胞克隆增强因子水平的研究被引量：2

A study on serum pre-B-cell colony-enhancing factor(PBEF) level in sepsis children with neutropenia

下载PDF

导出

摘要目的研究前B细胞克隆增强因子(PBEF)在中性粒细胞缺乏状态合并脓毒症时的水平变化及临床应用价值。方法选取28例急性淋巴细胞白血病(ALL)化疗后处于中性粒细胞缺乏状态的患儿为研究对象,其中无感染14例,脓毒症14例。收集所有患儿的临床资料及血清标本,用酶联免疫吸附法(ELISA)检测PBEF浓度,比较两组PBEF水平,分析PBEF与临床常用感染指标CRP、PCT的相关性,探讨中性粒细胞缺乏时PBEF在脓毒症的临床应用价值。结果脓毒症组PBEF浓度为(5.526±1.548)ng/mL,无感染组PBEF浓度为(5.184±1.295)ng/mL,两组PBEF水平比较无明显差异(p=0.536)。脓毒症组PBEF与其他常见炎性指标CRP、PCT无显著相关(尸值分别为0.159和0.311)。结论中性粒细胞缺乏状态合并脓毒症时PBEF水平无明显改变,可能与外周血中合成和分泌PBEF的细胞减少相关,PBEF是否可作为感染指标应用于临床有待进一步探讨。 Objective To investigate the level and clinical significance of serum pre-B-cell colony-enhancing factor （PBEF） in sepsis children with neutropenia. Methods We selected 28 cases of chemotherapy-induced neutropenia in childhood acute lymphoblastic leukemia, including 14 cases without infectious complications and 14 cases with sepsis. Serum specimens and clinical data from all enrolled children were collected. Serum level of PBEF was detected by enzyme-linked immunosorbent assay （ELISA）. Compared serum PBEF level of two groups and analyzed the correlations between PBEF and other clinical infectious biomakers, such as CRP and PCT, and discussed the clinical application value of PBEF in sepsis with neutropenia. Results Serum PBEF level in sepsis group was （5. 526 ± 1. 548） ng/mL, in patients without infectious complications it was （ 5. 184 ± 1. 295 ） ng/mL. There was no significant difference in serum PBEF level between two groups （P = 0. 536 ）. PBEF has no correlations with clinical infectious biomakers CRP or PCT. Conclusions Serum level of PBEF has no significant change in children with neutropenia, it may result from the lack of blood cells to synthesize and secrete PBEF, further researches are needed to establish whether PBEF can used as a maker for infection.

作者宁海萍蓝丹李新叶高宗燕李琳迪李登峰

机构地区广西医科大学第一附属医院儿科

出处《中国小儿血液与肿瘤杂志》 CAS 2016年第2期98-101,103,共5页 Journal of China Pediatric Blood and Cancer

基金国家自然科学基金(No.81060045) 国家自然科学基金(No.81170482) 广西壮族自治区研究生创新课题项目(YCSZ2014100)

关键词中性粒细胞缺乏脓毒症前B细胞克隆增强因子儿童白血病急性淋巴细胞性 Neutropenia Sepsis Pre-B-cell colony-enhancing factor（PBEF） Children Acute lymphoblastic leukemia （ALL）

分类号 R459.7 [医药卫生—急诊医学] R557.3 [医药卫生—血液循环系统疾病]

引文网络
相关文献

参考文献18

1Galli M,van Gool F,Rongvaux A,et al.The nicotinamide phosphorihosyltransferase:a molecular link between metabolism,inflammation,and cancer.Cancer Res,2010,70:8-11.
2Sun Z,Lei H,Zhang Z.Pre-B cell colony enhancing factor(PBEF),a cytokine with multiple physiological functions.Cytokine Growth Factor Rev,2013,24:433-442.
3Moreno-Vinasco L,Quijada H,Sammani S,et al.Nicotinamide phosphorihosyltransferase inhibitor is a novel therapeutic candidate in murine models of inflammatory lung injury.Am J Resp Cell Mol,2014,51:223-228.
4Busso N,Karababa M,Nobile M,et al.Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD.PLoS one,2008,3:e2267.
5Jia SH,Li Y,Parodo J,et al.Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis.J Clin Invest,2004,113:1318-1327.
6顾龙君.儿童急性淋巴细胞白血病诊疗建议(第三次修订草案)[J].中华儿科杂志,2006,44(5):392-395. 被引量：473
7高戈,冯喆,常志刚,唐普贤,佟宏峰.2012国际严重脓毒症及脓毒性休克诊疗指南[J].中华危重病急救医学,2013,25(8):501-505. 被引量：639
8Roberts KJ,Cross A,Vasieva 0,et al.Inhibition of pre-B cell colony-enhancing factor(PBEF/NAMPT/visfatin)decreases the ability of human neutrophils to generate reactive oxidants but does not impair bacterial killing.J Leukoc Biol,2013,94:481-492.
9王莹,史柳红.再论儿童脓毒症——如何早期识别和治疗严重脓毒症和脓毒性休克[J].临床儿科杂志,2012,30(1):1-5. 被引量：23
10Wenneras C,Hagberg L,Andersson R,et al.Distinct inflammatory mediator patterns characterize infectious and sterile systemic inflammation in febrile neutropenic hematology patients.PLoS One,2014,9;e92319.

二级参考文献30

1樊寻梅,武志远.国际儿科脓毒症定义会议介绍[J].中华儿科杂志,2005,43(8):618-620. 被引量：90
2Watson RS,Carcillo JA.Scope and epidemiology of pedia-tric sepsis[J].Pediatr Crit Care Med,2005,6(3 Suppl):S3-S5.
3Goldstein B,Giroir B,Randolph A,et al.International pediatric sepsis consensus conference:definitions for sepsis and organ dysfunction in pediatrics[J].Pediatr Crit Care Med,2005,6(1):2-8.
4Bone RG,Balk RA,Carra FB,et a1.Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis.The ACCP/SCCM Consensus Confe-rence Committee[J].Chest,1992,101(6):1644-1655.
5Gabriel JH.Early goal-directed therapy of pediatric septic shock in the emergency department[J].Israeli Emerg Med,2007,7(2):5-16.
6Levy MM,Dellinger RP,Towmsend SR,et al.The Survi-ving Sepsis Campaign:results of an international guideline-based performance improvement program targeting severe sepsis[J].Intensive Care Med,2010,36(2):222-231.
7Rivers E,Nguyen B,Havstad S,et al.Early goal-directed therapy in the treatment of severe sepsis and septic shock[J].N Engl J Med,2001,345(19):1368-1377.
8Dellinger RP,Levy MM,Carlet JM,et al.Surviving Sepsis Campaign:international guidelines for management of severe sepsis and septic shock:2008[J].Crit Care Med,2008,36(1):296-327.
9Oliveira CF,Nogueira de Sá FR,Oliveira DS,et al.Time-and fluid-sensitive resuscitation for hemodynamic support of children in septic shock:barriers to the implementation of the American College of Critical Care Medicine/Pediatric Advanced Life Support Guidelines in a pediatric intensive care unit in a developing world[J].Pediatr Emerg Care,2008,24(12):810-815.
10Cruz AT,Perry AM,Williams EA,et al.Implementation of goal-directed therapy for children with suspected sepsis in the emergency department[J].Pediatrics,2011,127(3):e758-e766.